PTC Therapeutics, Inc. revenue
PTC Therapeutics, Inc.'s revenue was $1.73bn in fiscal 2025, up 114.5% on the year before. Since fiscal 2011 ($105m) it has grown at a compound 22.1% a year. Over the last twelve months it was $1.16bn.
Revenue history
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 105 | 34 | 35 | 25 | 37 | 83 | 194 | 265 | 307 | 381 | 539 | 699 | 938 | 807 | 1,731 | 1,156 |
| Growth on the year before | — | −67.8% | +2.2% | −27.2% | +45.6% | +124.9% | +135.0% | +36.2% | +16.0% | +24.0% | +41.4% | +29.7% | +34.2% | −14.0% | +114.5% | — |
| Gross profit | — | — | — | — | — | — | 190 | 252 | 295 | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | 97.6% | 95.2% | 96.0% | — | — | — | — | — | — | — |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Collaboration and License Revenue | $998M | ▲ 328306.9% |
| Products | $587M | ▲ 0.8% |
| Royalty | $244M | ▲ 19.8% |
| Translarna1 | $235M | ▼ 26.7% |
| Emflaza | $146M | ▼ 29.4% |
| Sephience | $111M | — |
| Upstaza and Kebilidi | $56.6M | ▲ 234.8% |
| Other Products | $37.3M | ▲ 0.9% |
| Translarna | -$98.6M | ▼ 624.5% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | YoY |
|---|---|---|
| United States | $252M | ▲ 21.7% |
| Outside the US | $236M | ▼ 40.1% |
| All Other Countries Other Than Russia Brazil and United States | $168M | ▼ 14.7% |
| RU | $100M | ▼ 4.7% |
| Brazil | $65.7M | ▼ 8.9% |
These categories overlap or exclude eliminations, so shares aren't shown.
From PTC Therapeutics, Inc.'s 10-K filed February 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| PTC Therapeutics, Inc. | $1.16bn | -35.1% | 13.1% |
| Acadia Pharmaceuticals Inc | $1.14bn | 11.8% | 27.4% |
| Lakefront Biotherapeutics NV | $1.26bn | 321.6% | — |
| Madrigal Pharmaceuticals, Inc. | $1.28bn | 149.0% | — |
| Legend Biotech Corp | $1.03bn | 64.0% | — |
| Kiniksa Pharmaceuticals International, plc | $946m | 58.2% | 56.1% |
Compare with peers
- Acadia Pharmaceuticals Inc revenue
- Lakefront Biotherapeutics NV revenue
- Madrigal Pharmaceuticals, Inc. revenue
- Legend Biotech Corp revenue
- Kiniksa Pharmaceuticals International, plc revenue
Head to head: ACAD vs PTCTLKFT vs PTCTMDGL vs PTCT
More: Biotechnology stocks compared, Health Care sector, rankings of US companies